Key statistics
As of last trade AnaptysBio Inc (0HFQ:LSE) traded at 54.11, -5.47% below its 52-week high of 57.24, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 54.11 |
| Low | 54.11 |
| Bid | -- |
| Offer | -- |
| Previous close | 54.11 |
| Average volume | 302.86 |
|---|---|
| Shares outstanding | 27.69m |
| Free float | 26.02m |
| P/E (TTM) | -- |
| Market cap | 1.47bn USD |
| EPS (TTM) | -2.82 USD |
Data delayed at least 20 minutes, as of Feb 13 2026 18:37 GMT.
More ▼
- Anaptys Announces Participation at Upcoming Investor Conferences
- Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
- Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Anaptys Announces Participation in December Investor Conferences
- Anaptys Announces $100 Million Stock Repurchase Plan
- Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
- Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
- Anaptys Announces Participation in November Investor Conferences
- Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
- Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
More ▼
